The new funding rounds, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New funding rounds, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Industry Trends
See who's moving and how much in your market
No credit card required Weekly funding digest
TippingPoint Biosciences has raised $4.5M in a Seed round led by SOSV and LKS Fund to develop pioneering therapies for pediatric brain cancer.
PRIVATEMar 31, 2026•3 months ago
Amount Raised
$4.5 Million
Round Type
seed
San FranciscoBiotechnologyHealth CareMedicalTherapeutics
Investors
We CanXeiaAmerican Cancer Society Bright EdgeSontag Innovation FundStory House VenturesFreeflow VenturesSazze PartnersLks FundSosv
Description
TippingPoint Biosciences announced the closing of an oversubscribed $4.5 million seed financing for a breakthrough drug discovery platform. This platform targets epigenetic protein interfaces considered 'undruggable,' advancing precision medicine for pediatric cancers. The funding was led by SOSV and LKS Fund with contributions from other notable investors. The company aims to unlock new therapy targets for complex diseases.
Company Information
Company
TippingPoint Biosciences
Location
San Francisco, California, United States
About
TippingPoint Biosciences is a San Francisco-based therapeutic company focused on innovative drug discovery targeting the aberrant DNA in cancer cells. Led by CEO Dr. Laura Hsieh, the company has developed a novel platform for identifying first-in-class drugs for diseases related to dysfunctional DNA packaging. Their screening platform aims to directly target defective chromatin in disease cells while preserving healthy cells. The technology has applications in several disease areas, including cancer and neurodegenerative diseases.
San FranciscoBiotechnologyHealth CareMedicalTherapeutics